Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.95 |
| ▸ | ESR1 | P03372 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | TACR2 | P21452 | 2/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SHBG | P04278 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.63 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.63 |
| ▸ | HTR2C | P28335 | 1/20 | 0.63 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | TST | Q16762 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2468227 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL16432840 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL70443 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| Cardol SCHEMBL406402 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL4448056 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL68692 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL70292 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL70057 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL11737365 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 | |
| SCHEMBL17201654 | 1.00 | PTGS2 (1.00) | PTGS2CYP3A4ESR1ADRA2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029027-A1 | COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES | RENEW BIOPHARMA, INC. | 2023-01-26 | — | — | US | claimed |
| WO-2020210810-A9 | COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES | RENEW BIOPHARMA, INC. (US) | 2020-11-26 | — | — | WO | claimed |
| WO-2020210810-A1 | COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES | RENEW BIOPHARMA, INC. (US) | 2020-10-15 | — | — | WO | claimed |
| WO-2019183152-A1 | COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES | RENEW BIOPHARMA, INC. (US) | 2019-09-26 | — | — | WO | claimed |
| CN-101522738-A | Modified alkylresorcinol resins and applications thereof | INDSPEC CHEMICAL CORP (US) | 2009-09-02 | — | — | CN | claimed |
| EP-2087022-A1 | MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF | INDSPEC CHEMICAL CORPORATION (US) | 2009-08-12 | — | — | EP | claimed |
| WO-2008048839-A1 | MODIFIED ALKYLRESORCINOL RESINS AND APPLICATIONS THEREOF | INDSPEC CHEMICAL CORPORATION (US) | 2008-04-24 | — | — | WO | claimed |
| EP-4714444-A1 | PREPARATION FOR AND USE OF CANNABIDIOL DERIVATIVE DRUGS | Changchun Institute Of Applied Chemistry Chinese Academy Of Sciences (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-12540315-B2 | Compositions and methods for using genetically modified enzymes | RENEW BIOPHARMA, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| WO-2024239921-A1 | PREPARATION FOR AND USE OF CANNABIDIOL DERIVATIVE DRUGS | 中国科学院长春应用化学研究所 | 2024-11-28 | — | — | WO | disclosed |
| US-20230029027-A1 | COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES | RENEW BIOPHARMA, INC. | 2023-01-26 | — | — | US | disclosed |
| US-20210301267-A1 | COMPOSITIONS AND METHODS FOR USING GENETICALLY MODIFIED ENZYMES | RENEW BIOPHARMA, INC. | 2021-09-30 | — | — | US | disclosed |
| EP-1484376-A2 | Solvent adhesive | Ube Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20040206412-A1 | improved adhesion to joints; solvent adhesives | UBE INDUSTRIES, LTD. | 2004-10-21 | — | — | US | disclosed |
| US-20040171764-A1 | Joint to be adhered to nylon resin moldings | UBE INDUSTRIES, LTD. | 2004-09-02 | — | — | US | disclosed |
| US-20030131936-A1 | Surface in contact with the joint is a layer of a copolymerized nylon covered by a layer of a different nylon resin | UBE INDUSTRIES, LTD. | 2003-07-17 | — | — | US | disclosed |
| EP-1327518-A2 | Nylon resin multi-layer pipe and method for adhering same | Ube Industries, Ltd. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020066526-A1 | Joint to be adhered to nylon resin moldings | UBE INDUSTRIES, LTD. | 2002-06-06 | — | — | US | disclosed |
| EP-1195419-A2 | Joint for nylon resin moldings | Ube Industries, Ltd. (JP) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540315-B2 | Compositions and methods for using genetically modified enzymes | COASY, CYP4F3, CYP4F11 | PTGS2 2841/4885CYP3A4 165/4885ESR1 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.